4//SEC Filing
Kaye Randall 4
Accession 0000950170-24-096496
CIK 0001832168other
Filed
Aug 12, 8:00 PM ET
Accepted
Aug 13, 6:01 PM ET
Size
14.7 KB
Accession
0000950170-24-096496
Insider Transaction Report
Form 4
Kaye Randall
CMO
Transactions
- Purchase
Common Stock
2024-01-23$24.82/sh+100$2,482→ 100 total(indirect: By Spouse) - Sale
Common Stock
2024-06-25$20.87/sh−100$2,087→ 0 total(indirect: By Spouse) - Exercise/Conversion
Common Stock
2024-08-12$4.35/sh+16,667$72,501→ 34,587 total - Sale
Common Stock
2024-08-12$34.55/sh−10,476$361,948→ 24,111 total - Sale
Common Stock
2024-08-12$35.03/sh−6,191$216,856→ 17,920 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-08-12−16,667→ 129,633 totalExercise: $4.35Exp: 2033-02-08→ Common Stock (16,667 underlying)
Holdings
- 17,920
Common Stock
Footnotes (6)
- [F1]The amount represents restricted stock units that were granted on February 8, 2024, and reported in a Form 4 filed on February 9, 2024. The restricted stock units will vest in four equal annual installments commencing on February 8, 2025, and the shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units.
- [F2]The transaction reported in this line item of this Form 4 was effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.
- [F3]The amount includes the 17,920 restricted stock units described in footnote 1 of this Form 4.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.88 to $34.87, inclusive. The reporting person undertakes to provide Longboard Pharmaceuticals, Inc., any security holder of Longboard Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 4 and 5 to this Form 4.
- [F5]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.88 to $35.32, inclusive.
- [F6]The shares subject to the stock option vest and become exercisable in 48 equal monthly installments commencing March 9, 2023.
Documents
Issuer
Longboard Pharmaceuticals, Inc.
CIK 0001832168
Entity typeother
Related Parties
1- filerCIK 0001350416
Filing Metadata
- Form type
- 4
- Filed
- Aug 12, 8:00 PM ET
- Accepted
- Aug 13, 6:01 PM ET
- Size
- 14.7 KB